Vertex Pharmaceuticals stock sold off on two pipeline disappointments. The biotech company continues to grow with promising ...

Major indexes fell Tuesday as stocks gave back a chunk of the previous session's gains amid ongoing concerns about tariffs and the economic outlook.

The S&P 500 declined 0.5% on Tuesday, Aug. 5, 2025, as a key gauge of the services sector showed a slump in July and trade ...

Vertex Pharmaceuticals Inc.’s bad news from a phase II pain study and separately on the regulatory front caused shares ...

IBD 50 and IBD Big Cap 20 name Palantir Technologies PLTR surged around 7% and reached a record high on the stock market ...

Shares of biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) fell 17.4% in the afternoon session after the company announced its experimental pain drug, VX-993, failed a key mid-stage clinical trial ...

Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic ...

In connection with earnings, Vertex announced topline results from the Phase 2 study evaluating the safety and efficacy of VX ...

Key Takeaways U.S. equities declined at midday following a soft services industry report and President Donald Trump's ...

Vertex Pharmaceuticals Incorporated (VRTX) is currently at $389.64, down $82.63 or 17.5% --Would be lowest close since Dec. 12, 2023, when it closed at $357.73 --On pace for largest percent decrease ...

Vertex Pharmaceuticals (VRTX) posts strong Q2 earnings and revenue growth but faces a 17% stock drop after mid-stage pain drug failure. Read more here.